theclearbcd

Tools & Tech: WordPress, woocommerce

Project link: https://theclearcbd.com/

It’s tempting to think of cannabidiol (CBD), a non-psychoactive compound in cannabis, as an herbal panacea. After all, it’s being touted as a potential treatment for asthma, obesity, drug addiction, acne, Alzheimer’s, migraines, PTSD and insomnia, just to name a few conditions.

But research into CBD’s healthful properties has largely been stifled in the United States, until recently. So, much of the evidence is either historical (“Napoleon’s troops probably used it!”), anecdotal (“My aunt swears by it!”) or based on lab studies of animals (the rat was unavailable for comment).

However, times are changing. The June 2018 decision by the U.S. Food and Drug Administration to approve a cannabis-derived CBD drug called Epidiolex for treating certain forms of epilepsy is a positive sign that barriers to cannabis research could soon be a thing of the past. When you consider 30 states plus the District of Columbia have approved some form of medical cannabis, the need for answers and more CBD research is obvious.

We do know that cannabidiol is a key chemical messenger in the body’s endocannabinoid system, which is responsible for maintaining homeostasis and other functions from head to toe. (And there are claims CBD topicals can help with dandruff, athlete’s foot and everything in between).

There is a growing body of CBD research exploring the anti-inflammatory, anti-anxiety, anti-cancer, anti-you-name-it properties of cannabidiol. There are few definitive results yet. But urgent health needs, plus hundreds of CBD products trying to answer them, have a way of putting public demand ahead of the research curve.